CVX heads into Q2 earnings week with shorts neutralised and options turning cautious

The positioning story has essentially resolved. Short interest has fallen to just 0.92% of free float, down 11.6% over the past month, having peaked near 24 million shares in early April during the tariff-driven selloff. That reversal is now complete — there is no meaningful short overhang left to unwind. The borrow market reinforces the picture: availability is completely unconstrained, with shares available to lend running at multiples of the outstanding short position, and cost to borrow at a negligible 0.33% annually. The lending market has generated zero friction throughout the unwind. What's shifted this week is the options signal. The put/call ratio has crept up to 0.81, above its 20-day average of 0.78 and modestly above the recent mid-week readings in the 0.74–0.76 range. The z-score of 0.83 is not alarming, but the directional move — PCR rising into an earnings week after several quiet sessions — suggests hedging demand is picking up as May 27 approaches.

The Street presents a mild bull majority with a notable neutraliser in the mix. The bulk of recent analyst activity through early May was constructive: UBS raised its target to $220 while keeping a Buy, RBC reiterated Outperform at $220, and Citigroup's target sits at $235. The dissent comes from Bernstein, which cut its target from $216 to $204 on May 11 while holding at Market Perform — a signal that at least one firm sees the valuation as stretched after the rally. Barclays also remains at Equal-Weight with a $192 target, actually below the current price. The mean target of $214.87 implies roughly 9% upside from current levels, a spread that has compressed noticeably as the stock has rallied. On valuation, the trailing P/E has edged up to 14.9x — up nearly 0.8 turns over the week — while EV/EBITDA at 6.8x is slightly off its 30-day high. Factor scores paint a broadly supportive picture: EPS momentum ranks in the 87th percentile over 90 days, dividend quality scores in the 96th percentile, and the short score rank of 82 reflects how decisively shorts have stepped back. The ORTEX short score itself, at 28.3, remains low and has been stable, suggesting no fresh bearish conviction from the lending community.

The one angle that merits attention ahead of the print is insider activity. Director John Hess sold just over $36 million of stock on May 6 across three tranches, at prices in the $184–$185 range — well below the current quote. CEO Mike Wirth sold roughly $30 million in early March. These are large-cap executive sales of the kind that frequently occur under pre-set plans, and the trade significance scores are modest. But the cluster of senior selling in Q1 and early Q2, while the stock was trading below $215, is a data point the Street will note now that the stock has moved back toward those levels.

The last Q1 earnings print on May 1 produced a flat day-one reaction of -0.5% followed by a -6% five-day drift. Q2 results on May 27 arrive with the stock $6 higher than it was when that drift ended — meaning the bar heading into next week's report is meaningfully higher than it was a fortnight ago.